Browse more cannabis research, findings, methods, and limitations.
Five waves of national data show cannabis use among cancer patients rose at the same rate as the general population (55-60%) from 2013-2019, regardless of state legalization status.
Study of 148 people with cannabis use disorder found women used cannabis more in negative emotional contexts than men, with childhood stress linking to coping-motivated use in both genders.
Among 188 young heart attack patients (all smokers), the 41% who used cannabis had significantly worse cardiovascular outcomes over 3 years.
CBD given during repeated social stress in mice prevented social avoidance and enhanced cocaine vulnerability while normalizing serotonin, endocannabinoid, and stress hormone gene expression.
Mouse study shows cannabinoid receptor activation reduces brain damage after intracerebral hemorrhage by suppressing NOX-2 and the NLRP3 inflammasome.
Focus groups with 15 clinicians found tobacco cessation is overlooked in cannabis treatment settings, with healthcare fragmentation and training gaps as key barriers.
Study of 15,000+ Washington young adults found cannabis use rose through age 22 then plateaued, with social acceptability and low perceived harm as the strongest drivers.
Lab study provides first evidence that CBD suppresses HLA-G, a molecule tumors use to hide from the immune system, in choriocarcinoma cells.
Quebec birth cohort found teens who started cannabis early and used frequently had 51% more mental health visits and 86% more physical health visits by age 23 compared to nonusers.
Global Burden of Disease data shows cannabis use disorders affect an estimated 5.6 million people in the Americas (31.5% of all drug use disorders), second only to opioids.
Analysis of national survey data found medical cannabis laws reduced opioid misuse by 43% among cannabis users, but had no effect at the population level.
Study of 199 youth found blood endocannabinoid levels tracked with anxiety severity, and 2-AG increases during SSRI treatment predicted better response in adolescents with GAD.
Study of 257 women found cannabis use during pregnancy independently predicted higher postpartum PTSD and depression, separate from the effects of intimate partner violence.
Randomized study in 40 cats found 2 weeks of CBD reduced fear-related urination during thunderstorm simulations compared to placebo.
Survey of 3,900 Japanese cannabis users found cannabis was rarely a gateway to harder drugs, with odds of progressing to methamphetamine at just 0.08.
RCT of 1,078 young adults found text-message motivational treatment advanced participants through stages of change, resulting in 50% lower THC levels and 4 fewer use days at 6 months.
RCT of 1,078 young adults found text-message CUD treatment worked indirectly through increased motivation and harm reduction strategies, reducing cannabis use at 6 months.
Traditional Thai medicine containing cannabis leaves reversed stress-induced cognitive impairment in mice through antioxidant pathways, with THC and THCA identified as active compounds.
Focus groups with 77 cannabis consumers found most ignore existing product warnings and want cited sources, direct language, and visuals to make health warnings credible.
Systematic review of 29 studies found limited evidence for sex differences in acute cannabis cognitive effects, though females showed greater impairment in the few studies that found differences.
Pilot RCT of nabilone for obesity was stopped early due to poor tolerability at 6 mg/day, but low-dose (2 mg/day) showed preliminary weight loss and gut microbiome changes in just 4 completers.
Survey of 472 SUD treatment patients found cannabis flower dominates use patterns, with THC potency driving purchases, though some chose CBD for perceived medical benefits.
Interviews with 23 Canadians in cannabis treatment found recreational use is still seen as masculine, women face extra stigma, but legalization may be shifting these norms.
Survey of 544 SUD treatment patients found cannabis use linked to more trauma and psychiatric diagnoses, but trauma may explain the cannabis-mental health connection.
Review finds THC and CBD show multiple anticancer mechanisms against cervical cancer in preclinical studies, with nanotechnology delivery and combination therapies enhancing potential.
Youth ages 15-20 built a systems model identifying 14 feedback loops showing how romantic relationship stress and cannabis use reinforce each other.
Japanese national survey found cannabis patients were younger with less severe disorders than methamphetamine patients, but less connected to recovery support services.
Review examines the cannabis-ADHD connection, finding elevated cannabis use risk in ADHD and early evidence that CBD may have therapeutic potential through dopamine pathway modulation.
Study of 388 tibia fracture patients found preoperative marijuana use was not associated with increased surgical complications, infections, or healing problems.
Phase I trial of a CBD-hydroxychloroquine combination for inflammatory conditions showed good tolerability and bioavailability in 36 healthy volunteers.
Australian early psychosis service found medicinal cannabis THC concentrations nearly doubled in prescriptions written after psychosis onset, with 60% of patients experiencing attributed deterioration.
Systematic review of 17 studies finds cannabis decriminalization and legalization reduce arrests by 13-87%, but racial disparities in enforcement persist.
Survey of 385 Australian cannabis users found 21.5% drove within 3 hours of use, with heavy users and those unconcerned about testing most likely to drive soon after consuming.
Cold water immersion stress test did not release stored THC into the blood or cause intoxication in 15 regular cannabis users, despite triggering measurable stress and fat breakdown.
National survey finds only a third of US dentists screen teens for cannabis use annually, and most who screen never provide counseling, despite expressing willingness.
Analysis of 7 CUD trials found urinary THC dropped about 50% in self-reported reducers, but no reliable individual-level cut-point could be established.
Educational intervention about medical cannabis for fibromyalgia quadrupled referral rates from 4% to 17% in a single rheumatology clinic.
Five-year Canadian prospective study found cannabis use increased modestly after legalization while misuse decreased, with the largest improvements among frequent pre-legalization users.
Canadian data shows legal cannabis captured 72% of the market and illegal share fell to 24% within 5 years of legalization, but total cannabis spending grew 75%.
A novel drug delivery technology dramatically improved CBD absorption and brain levels in rats, showing anti-seizure effects at potentially lower doses than Epidiolex.
Rigorous analysis of Medicare chronic pain patients in 7 states found medical cannabis laws had no measurable effect on opioid treatment or overdose-related healthcare.
NYC longitudinal study found edible cannabis surpassed smoking as the most common method among young adults, with new users far outnumbering quitters.
First study of cannabis use in stem cell transplant patients found use shifted from smoking to pharmaceutical products, with increased provider engagement post-transplant.
Survey finds U.S. parents split on CBD product safety for children, with many unaware of rising pediatric poison control calls.
Missouri college students showed more positive cannabis attitudes and higher use intentions after the state legalized recreational cannabis.
Study finds a link between more frequent cannabis use and greater gambling involvement, suggesting shared risk factors.
Randomized simulator trial finds cannabis impairs driving performance even when users feel capable, highlighting a dangerous perception gap.
Arizona cannabis-related hospitalizations rose significantly from 2016 to 2021, spanning the pre- and post-recreational legalization period.
The Dunedin Study found long-term cannabis users have distinct DNA methylation patterns, suggesting lasting epigenetic effects from decades of use.
Hospital admissions for cannabis use disorder among pregnant women are increasing, highlighting a growing clinical concern around prenatal cannabis exposure.